Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Sandy_Macrae
|
| gptkbp:collaboratedWith |
gptkb:Pfizer
gptkb:Takeda gptkb:Biogen gptkb:Sanofi |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies for genetic diseases
|
| gptkbp:focusesOn |
genomic medicine
genome editing gene therapy |
| gptkbp:founded |
1995
|
| gptkbp:founder |
gptkb:Edward_O._Lanphier_II
|
| gptkbp:headquartersLocation |
gptkb:Brisbane,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sangamo Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:ST-920_(gene_therapy_for_Fabry_disease)
gptkb:TX200_(CAR-Treg_cell_therapy) SB-525 (gene therapy for hemophilia A) |
| gptkbp:numberOfEmployees |
~300 (2023)
|
| gptkbp:stockSymbol |
gptkb:SGMO
|
| gptkbp:technology |
zinc finger nucleases
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_SGMO
|
| gptkbp:website |
https://www.sangamo.com/
|
| gptkbp:bfsParent |
gptkb:SGTX
|
| gptkbp:bfsLayer |
5
|